Revenue of $8.55 billion increased 1% sequentially and decreased 6% year on year GAAP EPS of $0.74 increased 28% sequentially ...

Among these, GlaxoSmithKline and Debiopharm/Merck have drug candidates that are in the most advanced phase of development—Phase III clinical trials.